NASDAQ:MTEM - Molecular Templates Stock Price, Price Target & More

Get Started

$6.76 -0.14 (-2.03 %)

(As of 05/24/2018 04:00 PM ET)

Previous Close$6.90

Today's Range$6.68 - $6.93

52-Week Range$3.85 - $13.25

Volume49,500 shs

Average Volume67,718 shs

Market Capitalization$186.18 million

P/E Ratio-3.21

Dividend YieldN/A

Beta3.15

About Molecular Templates (NASDAQ:MTEM)

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. The company primarily develops a pipeline of engineered toxin bodies. Its lead drug candidate is MT-3724 that is in a Phase I clinical trial for the treatment of relapsed/refractory non-Hodgkin's lymphoma and B-cell lymphoma. The company also develops MT-4019, a preclinical drug candidate targeting CD38; and other candidates that are in pre-clinical development for the treatment of solid and hematological cancers. Molecular Templates, Inc. is headquartered in Austin, Texas.

Receive MTEM News and Ratings via Email

Sign-up to receive the latest news and ratings for MTEM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:MTEM

CUSIP88580720

Webwww.mtem.com

Phone512-869-1555

Debt

Debt-to-Equity Ratio0.04

Current Ratio4.54

Quick Ratio4.54

Price-To-Earnings

Trailing P/E Ratio-3.21

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$3.39 million

Price / Sales53.96

Cash FlowN/A

Price / CashN/A

Book Value$2.62 per share

Price / Book2.58

Profitability

EPS (Most Recent Fiscal Year)($2.11)

Net Income$-23,140,000.00

Net Margins-514.16%

Return on Equity-40.24%

Return on Assets-33.82%

Miscellaneous

Employees38

Outstanding Shares27,060,000

Molecular Templates (NASDAQ:MTEM) Frequently Asked Questions

What is Molecular Templates' stock symbol?

Molecular Templates trades on the NASDAQ under the ticker symbol "MTEM."

When did Molecular Templates' stock split? How did Molecular Templates' stock split work?

Shares of Molecular Templates reverse split on Wednesday, August 2nd 2017. The 1-11 reverse split was announced on Tuesday, August 1st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 1st 2017. An investor that had 100 shares of Molecular Templates stock prior to the reverse split would have 9 shares after the split.

How were Molecular Templates' earnings last quarter?

Molecular Templates Inc. (NASDAQ:MTEM) posted its quarterly earnings data on Monday, May, 14th. The biotechnology company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.25) by $0.07. The biotechnology company had revenue of $0.48 million for the quarter. Molecular Templates had a negative return on equity of 40.24% and a negative net margin of 514.16%. View Molecular Templates' Earnings History.

When is Molecular Templates' next earnings date?

Molecular Templates is scheduled to release their next quarterly earnings announcement on Monday, July, 30th 2018. View Earnings Estimates for Molecular Templates.

What price target have analysts set for MTEM?

2 analysts have issued 12 month price targets for Molecular Templates' stock. Their predictions range from $0.40 to $10.00. On average, they anticipate Molecular Templates' share price to reach $5.20 in the next year. View Analyst Ratings for Molecular Templates.

Who are some of Molecular Templates' key competitors?

Some companies that are related to Molecular Templates include Arcus Biosciences (RCUS), CymaBay Therapeutics (CBAY), Dova Pharmaceuticals (DOVA), ANI Pharmaceuticals Inc Common Stock (ANIP), Dicerna Pharmaceuticals (DRNA), Geron (GERN), BeyondSpring (BYSI), Five Prime Therapeutics (FPRX), Rigel Pharmaceuticals (RIGL), Lannett (LCI), Odonate Therapeutics (ODT), Ziopharm Oncology (ZIOP), ChemoCentryx (CCXI), Keryx Biopharmaceuticals (KERX) and Aduro BioTech (ADRO).

Who are Molecular Templates' key executives?

Molecular Templates' management team includes the folowing people:

Dr. Eric E. Poma Ph.D., CEO, Chief Scientific Officer & Director (Age 46)
Ms. Jason S Kim, Pres & COO (Age 43)
Mr. Adam D. Cutler B.A., Chief Financial Officer
Dr. Barbara A. Ruskin Ph.D., J.D., Sr. VP, Gen. Counsel & Chief Patent Officer
Mr. Kurt Elster, Exec. VP of Corp. Devel. (Age 51)

Has Molecular Templates been receiving favorable news coverage?

News coverage about MTEM stock has trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Molecular Templates earned a daily sentiment score of 0.07 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 47.21 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Who are Molecular Templates' major shareholders?

Molecular Templates' stock is owned by many different of institutional and retail investors. Top institutional investors include Caxton Corp (3.84%), BVF Inc. IL (2.54%), First Eagle Investment Management LLC (2.28%), Lyon Street Capital LLC (1.14%), Millennium Management LLC (1.09%) and JPMorgan Chase & Co. (0.18%). View Institutional Ownership Trends for Molecular Templates.

Which major investors are selling Molecular Templates stock?

MTEM stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL and First Eagle Investment Management LLC. View Insider Buying and Selling for Molecular Templates.

Which major investors are buying Molecular Templates stock?

MTEM stock was acquired by a variety of institutional investors in the last quarter, including Lyon Street Capital LLC, Millennium Management LLC, Dimensional Fund Advisors LP, Caxton Corp, JPMorgan Chase & Co., Alps Advisors Inc. and Northern Trust Corp. View Insider Buying and Selling for Molecular Templates.

How do I buy shares of Molecular Templates?

Shares of MTEM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Molecular Templates' stock price today?

One share of MTEM stock can currently be purchased for approximately $6.76.

How big of a company is Molecular Templates?

Molecular Templates has a market capitalization of $186.18 million and generates $3.39 million in revenue each year. The biotechnology company earns $-23,140,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Molecular Templates employs 38 workers across the globe.

How can I contact Molecular Templates?

Molecular Templates' mailing address is 9301 AMBERGLEN BLVD. SUITE 100, AUSTIN TX, 78729. The biotechnology company can be reached via phone at 512-869-1555 or via email at [email protected]

MarketBeat Community Rating for Molecular Templates (MTEM)

Community Ranking:		2.8 out of 5 ( )
Outperform Votes:		180 (Vote Outperform)
Underperform Votes:		142 (Vote Underperform)
Total Votes:		322

MarketBeat's community ratings are surveys of what our community members think about Molecular Templates and other stocks. Vote "Outperform" if you believe MTEM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MTEM will underperform the S&P 500 over the long term. You may vote once every thirty days.

Molecular Templates (NASDAQ:MTEM) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

2 Wall Street analysts have issued ratings and price targets for Molecular Templates in the last 12 months. Their average twelve-month price target is $5.20, suggesting that the stock has a possible downside of 23.08%. The high price target for MTEM is $10.00 and the low price target for MTEM is $0.40. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.50	2.50	2.50	2.50
Ratings Breakdown:	0 Sell Rating(s) 1 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$5.20	$5.20	$5.20	$5.20
Price Target Upside:	23.08% downside	862.96% upside	862.96% upside	862.96% upside

Molecular Templates (NASDAQ:MTEM) Consensus Price Target History

Price Target History for Molecular Templates (NASDAQ:MTEM)

Molecular Templates (NASDAQ:MTEM) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
8/3/2017	Ladenburg Thalmann	Initiated Coverage	Buy ➝ Buy	$10.00	High
8/3/2017	Stifel Nicolaus	Reiterated Rating	Hold	$0.40	Low
10/3/2016	William Blair	Reiterated Rating	Outperform		N/A
9/30/2016	S&P Equity Research	Lower Price Target		$7.37 ➝ $5.72	N/A

(Data available from 5/24/2016 forward)

Molecular Templates (NASDAQ:MTEM) Earnings History and Estimates Chart

Earnings by Quarter for Molecular Templates (NASDAQ:MTEM)

Molecular Templates (NASDAQ:MTEM) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.12 EPS

Molecular Templates (NASDAQ MTEM) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
7/30/2018		($0.25)					N/A
5/14/2018	Q1 2018	($0.25)	($0.32)		$0.48 million	View	N/A
3/28/2018	Q4 2017	($0.20)	($0.26)		$0.82 million	View	N/A
11/14/2017	Q3 2017		($0.62)		$0.65 million	View	N/A
7/31/2017	Q2 2017	($0.77)	$0.22		$3.00 million	View	N/A
5/15/2017	Q1 2017	($0.88)	($0.77)			View	N/A
3/27/2017	Q4 2016	($0.77)	($0.55)			View	N/A
11/7/2016	Q3	($0.99)	($0.88)			View	N/A
8/1/2016	Q216	($1.10)	($1.10)			View	N/A
5/5/2016	Q1	($0.22)	($1.21)			View	N/A
3/10/2016	Q4	($1.21)	$9.46	$4.51 million	$65.87 million	View	N/A
11/2/2015	Q315	($1.54)	($0.99)	$3.69 million	$3.70 million	View	N/A
7/30/2015	Q2	($1.54)	($1.32)	$3.70 million	$3.68 million	View	N/A
4/30/2015		($1.54)	($1.87)	$3.44 million	$3.68 million	View	N/A
3/3/2015	Q414	($1.43)	($1.32)	$4.34 million	$3.68 million	View	N/A
11/3/2014	Q314	($1.32)	($1.65)	$3.82 million	$3.70 million	View	N/A
8/1/2014		($1.43)	($1.32)	$4.00 million	$3.68 million	View	N/A
5/1/2014		($1.10)	($1.32)	$9.81 million	$3.68 million	View	N/A
3/6/2014	Q413	($1.10)	($1.43)	$3.58 million	$3.20 million	View	N/A
11/4/2013	Q313	($1.54)	$0.22	$3.15 million	$3.20 million	View	N/A
8/1/2013	Q2 2013	($0.99)	($1.32)	$3.69 million	$3.18 million	View	N/A
5/2/2013	Q1 2013	($0.99)	($1.76)	$2.80 million	$2.90 million	View	N/A
3/7/2013	Q4 2012	($1.32)	($5.06)			View	N/A
11/2/2012	Q312	($0.66)	($0.66)	$2.29 million	$1.80 million	View	N/A
8/2/2012	Q2 2012	($1.10)	($0.44)			View	N/A
5/3/2012	Q1 2012	$1.65	($1.56)			View	N/A
3/8/2012	Q4 2011	($1.54)	($1.58)			View	N/A
11/3/2011	Q3 2011	($1.65)	($1.76)			View	N/A
8/4/2011	Q2 2011	($1.76)	($1.78)			View	N/A
5/12/2011	Q1 2011	($1.87)	($2.52)			View	N/A
3/24/2011	Q4 2010	($2.31)	($2.13)			View	N/A
11/4/2010	Q3 2010	($2.20)	($1.94)			View	N/A
8/5/2010	Q2 2010	($1.98)	($0.09)			View	N/A
5/7/2010	Q1 2010	($1.98)	($1.95)			View	N/A
3/4/2010	Q4 2009	($1.98)	($1.61)			View	N/A
11/5/2009	Q3 2009	($4.62)	($4.44)			View	N/A
8/6/2009	Q2 2009	($3.74)	($4.51)			View	N/A
5/7/2009	Q1 2009	($3.63)	($4.73)			View	N/A
3/5/2009	Q4 2008		($3.47)			View	N/A
11/6/2008	Q3 2008	($8.58)	($5.34)			View	N/A
8/7/2008	Q2 2008	($9.24)	($7.00)			View	N/A
5/7/2008	Q1 2008		($8.84)			View	N/A
3/6/2008	Q4 2007		($13.13)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Molecular Templates (NASDAQ:MTEM) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Molecular Templates (NASDAQ MTEM) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 12.97%
Institutional Ownership Percentage: 19.23%

Insider Trading History for Molecular Templates (NASDAQ:MTEM)

Institutional Ownership by Quarter for Molecular Templates (NASDAQ:MTEM)

Molecular Templates (NASDAQ MTEM) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/1/2017	Jeffrey W Bird	Director	Buy	510,703	$0.57	$291,100.71	919
2/18/2015	Wilfred E Jaeger	Director	Buy	25,000	$3.75	$93,750.00
10/13/2014	Nipun Davar	VP	Buy	3,000	$2.99	$8,970.00
10/1/2014	Hill Ventures Sutter	Major Shareholder	Sell	226,657	$3.77	$854,496.89
10/1/2014	Jeffrey W Bird	Director	Sell	238,520	$3.77	$899,220.40
6/20/2014	David L Anderson	Major Shareholder	Sell	13,988	$4.01	$56,091.88
1/16/2014	Wilfred Jaeger	Director	Sell	96,356	$4.86	$468,290.16
1/15/2014	Wilfred Jaeger	Director	Sell	424,956	$4.87	$2,069,535.72
1/10/2014	Wilfred Jaeger	Director	Sell	723,900	$4.88	$3,532,632.00
7/15/2013	Wilfred E Jaeger	Director	Sell	322,000	$5.53	$1,780,660.00
7/11/2013	Wilfred E Jaeger	Director	Sell	178,000	$5.51	$980,780.00
7/5/2013	Wilfred E Jaeger	Director	Sell	219,667	$5.53	$1,214,758.51
6/19/2013	Wilfred E Jaeger	Director	Sell	2,000	$5.50	$11,000.00
6/18/2013	Wilfred E Jaeger	Director	Sell	124,733	$5.51	$687,278.83
6/10/2013	Wilfred E Jaeger	Director	Sell	153,600	$5.48	$841,728.00
5/31/2013	David L Anderson	Major Shareholder	Sell	266,542	$5.72	$1,524,620.24
5/31/2013	Jeffrey W Bird	Director	Sell	273,181	$5.72	$1,562,595.32
5/22/2013	Tillman Pearce	Insider	Sell	20,000	$5.63	$112,600.00

(Data available from 1/1/2013 forward)

Molecular Templates (NASDAQ MTEM) News Headlines

Source:

Date	Headline
	Molecular Templates (MTEM) to Present Clinical Data at ASCO www.streetinsider.com - May 17 at 4:02 PM
	Molecular Templates to Present Clinical Data at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018 finance.yahoo.com - May 17 at 10:01 AM
	Molecular Templates misses by $0.07 seekingalpha.com - May 15 at 4:13 PM
	Molecular Templates, Inc. Reports First Quarter 2018 Financial Results finance.yahoo.com - May 15 at 10:31 AM
	Molecular Templates (MTEM) Releases Earnings Results, Misses Expectations By $0.07 EPS www.americanbankingnews.com - May 15 at 8:13 AM
	Molecular Templates (MTEM) to Release Quarterly Earnings on Monday www.americanbankingnews.com - May 7 at 5:55 AM
	With A -91.25% Earnings Drop, Did Molecular Templates Inc (NASDAQ:MTEM) Really Underperform? finance.yahoo.com - April 27 at 3:55 PM
	Stifel Nicolaus Reiterates "Hold" Rating for Molecular Templates (MTEM) www.americanbankingnews.com - April 13 at 9:27 PM
	Molecular Templates (MTEM) Coverage Initiated by Analysts at Ladenburg Thalmann www.americanbankingnews.com - April 13 at 7:15 PM
	Molecular Templates (MTEM) Upgraded by ValuEngine to Hold www.americanbankingnews.com - April 13 at 1:36 PM
	ValuEngine Upgrades Molecular Templates (MTEM) to Sell www.americanbankingnews.com - April 8 at 11:19 AM
	Molecular Templates (MTEM) Upgraded at ValuEngine www.americanbankingnews.com - April 3 at 11:38 AM
	Molecular Templates misses by $0.06 seekingalpha.com - March 29 at 10:29 AM
	Molecular Templates, Inc. Reports Fourth Quarter 2017 Financial Results finance.yahoo.com - March 29 at 10:29 AM
	Molecular Templates (MTEM) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS www.americanbankingnews.com - March 29 at 7:37 AM
	Molecular Templates (MTEM) Raised to "Hold" at Zacks Investment Research www.americanbankingnews.com - March 27 at 7:58 PM
	BidaskClub Downgrades Molecular Templates (MTEM) to Hold www.americanbankingnews.com - March 25 at 9:50 AM
	Molecular Templates to Present at the Oppenheimer 28th Annual Healthcare Conference finance.yahoo.com - March 19 at 4:14 PM
	New Data on Molecular Templates’ Engineered Toxin Bodies to be Presented at the American Association of Cancer Research (AACR) Annual Meeting 2018 finance.yahoo.com - March 15 at 10:50 AM
	Molecular Templates (MTEM) Cut to "Sell" at ValuEngine www.americanbankingnews.com - March 4 at 2:22 PM
	Molecular Templates Closes $10 Million Debt Facility with Perceptive Advisors finance.yahoo.com - March 3 at 10:35 AM
	Molecular Templates (MTEM) Upgraded to "Hold" by ValuEngine www.americanbankingnews.com - February 4 at 9:46 PM
	Molecular Templates (MTEM) Downgraded by BidaskClub to Buy www.americanbankingnews.com - January 31 at 10:54 PM
	Financial Comparison: Threshold Pharmaceuticals (MTEM) & Madrigal Pharmaceuticals (MDGL) www.americanbankingnews.com - January 15 at 5:38 AM
	Molecular Templates Provides Corporate Update and Outlines 2018 Milestones finance.yahoo.com - January 5 at 9:01 AM
	DURECT (DRRX) & Threshold Pharmaceuticals (MTEM) Financial Analysis www.americanbankingnews.com - December 25 at 9:42 AM
	Threshold Pharmaceuticals (MTEM) Upgraded to Strong-Buy by BidaskClub www.americanbankingnews.com - December 23 at 1:28 PM
	Did Molecular Templates Inc (NASDAQ:MTEM) Create Value For Shareholders? finance.yahoo.com - December 19 at 5:51 PM
	Molecular Templates Inc (MTEM.OQ) www.reuters.com - December 8 at 5:43 PM
	GALT Faces Big Test Today, ABBV Clears Psoriasis Trial, DEPO Cuts 40% Of Staff www.rttnews.com - December 5 at 9:16 AM
	ValuEngine Lowers Threshold Pharmaceuticals (MTEM) to Sell www.americanbankingnews.com - December 3 at 6:30 AM
	Tesla Is the Exception That Proves the Rule on Board Pay www.bloomberg.com - November 30 at 9:03 AM
	Zacks Investment Research Lowers Threshold Pharmaceuticals, Inc. (MTEM) to Sell www.americanbankingnews.com - November 23 at 9:16 PM
	Molecular Templates to Present at the 29th Annual Piper Jaffray Healthcare Conference finance.yahoo.com - November 22 at 5:43 AM
	Global Pancreatic Cancer Market share will Increase US$ 13 Billion By 2021 www.marketwatch.com - November 15 at 6:33 AM
	Molecular Templates, Inc. Reports Third Quarter 2017 Financial Results finance.yahoo.com - November 15 at 6:33 AM
	Critical Contrast: Threshold Pharmaceuticals (MTEM) versus The Competition www.americanbankingnews.com - October 25 at 7:10 PM
	Molecular Templates Announces Dosing of First Patient in Phase 1 Expansion Study of MT-3724 in Diffuse Large B-Cell Lymphoma (DLBCL) finance.yahoo.com - October 25 at 7:48 AM
	Analyzing Threshold Pharmaceuticals (MTEM) & Cempra (CEMP) www.americanbankingnews.com - October 8 at 6:16 PM
	Molecular Templates to Present at the 2017 BIO Investor Forum finance.yahoo.com - October 6 at 9:32 AM
	Analyzing Threshold Pharmaceuticals (MTEM) & Its Peers www.americanbankingnews.com - October 3 at 8:26 AM
	Here's Why Spectrum Pharmaceuticals, Inc. Is Surging Today www.fool.com - September 28 at 6:59 PM
	Molecular Templates to Present at the BioCentury 24th Annual Newsmakers in the Biotech Industry Conference finance.yahoo.com - September 7 at 6:26 AM
	Molecular Templates to Ring NASDAQ Closing Bell Friday, September 1, 2017 finance.yahoo.com - August 31 at 7:30 AM
	Head to Head Survey: Corvus Pharmaceuticals (CRVS) vs. Threshold Pharmaceuticals (MTEM) www.americanbankingnews.com - August 23 at 4:26 AM
	Austin biotech company lands on Nasdaq with fresh $60 million www.bizjournals.com - August 17 at 5:27 AM
	Brokerages Anticipate Threshold Pharmaceuticals, Inc. (MTEM) Will Announce Earnings of -$0.33 Per Share www.americanbankingnews.com - August 16 at 2:14 PM
	Molecular Templates to Present at the 2017 Wedbush PacGrow Healthcare Conference finance.yahoo.com - August 15 at 2:22 AM
	Molecular Templates Potential Catalysts, Merger Synergies and Pipeline Review finance.yahoo.com - August 11 at 6:42 AM
	Takeda and Molecular Templates Announce Multi-Target Research and Licensing Collaboration to Develop Next-Generation Oncology Therapies www.businesswire.com - August 4 at 5:48 AM

Molecular Templates (NASDAQ:MTEM) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Molecular Templates (NASDAQ:MTEM) Income Statement, Balance Sheet and Cash Flow Statement

Molecular Templates (NASDAQ MTEM) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff